Showing results (1801-1810 of 1,906) with videos related to
Sort By:
Pageof 191
Plos One|January 27, 2012
Genetic mapping and exome sequencing identify variants associated with five novel diseasesErik G Puffenberger, Robert N Jinks, Carrie Sougnez, et al.Genetics in Medicine : Official Journal of the American College of Medical Genetics|October 18, 2018
Correction: TANGO2: expanding the clinical phenotype and spectrum of pathogenic variantsJennifer N Dines, Katie Golden-Grant, Amy LaCroix, et al.The Journal of General Virology|February 16, 2006
Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirusRaymond H See, Alexander N Zakhartchouk, Martin Petric, et al.Hepatology (Baltimore, Md.)|September 11, 2012
Ammonia control and neurocognitive outcome among urea cycle disorder patients treated with glycerol phenylbutyrateGeorge A Diaz, Lauren S Krivitzky, Masoud Mokhtarani, et al.Journal of Environmental Management|August 7, 2025
RAD (Resist-Accept-Direct) switch points and triggers for adaptation planningA J Lynch, J D Ashander, T W Ciocco, et al.Genetics in Medicine : Official Journal of the American College of Medical Genetics|December 16, 2014
Blood ammonia and glutamine as predictors of hyperammonemic crises in patients with urea cycle disorderBrendan Lee, George A Diaz, William Rhead, et al.Genetics in Medicine : Official Journal of the American College of Medical Genetics|September 25, 2018
TANGO2: expanding the clinical phenotype and spectrum of pathogenic variantsJennifer N Dines, Katie Golden-Grant, Amy LaCroix, et al.Science (New York, N.Y.)|May 15, 2012
Dawn at Vesta: testing the protoplanetary paradigmC T Russell, C A Raymond, A Coradini, et al.Global Change Biology|September 19, 2017
Vegetation demographics in Earth System Models: A review of progress and prioritiesRosie A Fisher, Charles D Koven, William R L Anderegg, et al.The Lancet. Oncology|March 29, 2023
Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trialChristopher J Sweeney, Andrew J Martin, Martin R Stockler, et al.Pageof 191